Cardio Diagnostics Holdings/$CDIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cardio Diagnostics Holdings
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
Ticker
$CDIO
Sector
Primary listing
Employees
14
Headquarters
Website
CDIO Metrics
BasicAdvanced
$6.4M
-
-$4.50
2.91
-
Price and volume
Market cap
$6.4M
Beta
2.91
52-week high
$5.70
52-week low
$3.22
Average daily volume
39K
Financial strength
Current ratio
23.548
Quick ratio
21.59
Long term debt to equity
3.108
Total debt to equity
6.408
Interest coverage (TTM)
-380.46%
Profitability
EBITDA (TTM)
-5.853
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-32,040.48%
Operating margin (TTM)
-31,972.31%
Management effectiveness
Return on assets (TTM)
-54.15%
Return on equity (TTM)
-97.67%
Valuation
Price to revenue (TTM)
259.149
Price to book
0.65
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-0.881
Free cash flow yield (TTM)
-113.50%
Free cash flow per share (TTM)
-4.131
Growth
Revenue change (TTM)
-50.16%
Earnings per share change (TTM)
-68.09%
3-year revenue growth (CAGR)
178.71%
3-year earnings per share growth (CAGR)
-33.14%
CDIO News
AllArticlesVideos
Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
Business Wire·1 month ago
Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease
Business Wire·1 month ago
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cardio Diagnostics Holdings stock?
Cardio Diagnostics Holdings (CDIO) has a market cap of $6.4M as of August 22, 2025.
What is the P/E ratio for Cardio Diagnostics Holdings stock?
The price to earnings (P/E) ratio for Cardio Diagnostics Holdings (CDIO) stock is 0 as of August 22, 2025.
Does Cardio Diagnostics Holdings stock pay dividends?
No, Cardio Diagnostics Holdings (CDIO) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Cardio Diagnostics Holdings dividend payment date?
Cardio Diagnostics Holdings (CDIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardio Diagnostics Holdings?
Cardio Diagnostics Holdings (CDIO) has a beta rating of 2.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.